159 related articles for article (PubMed ID: 21158663)
1. JAK inhibition in myelofibrosis.
Arellano-Rodrigo E; Alvarez-Larrán A
N Engl J Med; 2010 Dec; 363(25):2464; author reply 2464-5; discussion 2465. PubMed ID: 21158663
[No Abstract] [Full Text] [Related]
2. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
Reilly JT; McMullin MF; Beer PA; Butt N; Conneally E; Duncombe AS; Green AR; Mikhaeel G; Gilleece MH; Knapper S; Mead AJ; Mesa RA; Sekhar M; Harrison CN
Br J Haematol; 2014 Nov; 167(3):418-20. PubMed ID: 24961987
[No Abstract] [Full Text] [Related]
3. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.
Tefferi A
N Engl J Med; 2012 Mar; 366(9):844-6. PubMed ID: 22375977
[No Abstract] [Full Text] [Related]
4. From palliation to targeted therapy in myelofibrosis.
Vannucchi AM
N Engl J Med; 2010 Sep; 363(12):1180-2. PubMed ID: 20843255
[No Abstract] [Full Text] [Related]
5. Incyte comes of age with JAK inhibitor approval.
Moran N
Nat Biotechnol; 2012 Jan; 30(1):3-5. PubMed ID: 22231071
[No Abstract] [Full Text] [Related]
6. Ruxolitinib for myelofibrosis.
Haznedaroglu IC
N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
[No Abstract] [Full Text] [Related]
7. Ruxolitinib for myelofibrosis.
Koschmieder S; Koppelle A; Seifert H
N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
[No Abstract] [Full Text] [Related]
8. Ruxolitinib for myelofibrosis.
Diamantidis MD
N Engl J Med; 2012 May; 366(21):2031; author reply 2032-4. PubMed ID: 22621633
[No Abstract] [Full Text] [Related]
9. Verruconis gallopava in a patient with myelofibrosis on ruxolitinib.
Hsu A; Ulici V
Blood; 2020 Apr; 135(14):1189. PubMed ID: 32243521
[No Abstract] [Full Text] [Related]
10. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
11. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
13. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib.
Mesa RA; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Feb; 11(2):103-4. PubMed ID: 22293561
[No Abstract] [Full Text] [Related]
17. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib: a review of its use in patients with myelofibrosis.
Plosker GL
Drugs; 2015 Feb; 75(3):297-308. PubMed ID: 25601187
[TBL] [Abstract][Full Text] [Related]
20. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Wysham NG; Sullivan DR; Allada G
Chest; 2013 May; 143(5):1478-1479. PubMed ID: 23648912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
